PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2022; 14(01): 006-011
DOI: 10.1055/s-0042-1748774
Review Article

Anemia in Chronic Kidney Disease Patients: An Update

Elmukhtar Habas 
1   Department of Medicine, Facharzt Internal Medicine, Facharzt Nephrology, Hamad General Hospital, Doha, Qatar
,
Amnna Rayani
2   Department of Hematology, Facharzt Pediatric, Facharzt Hemato-Oncology, Tripoli Children Hospital, Tripoli University, Tripoli, Libya
,
Aml M. Habas
2   Department of Hematology, Facharzt Pediatric, Facharzt Hemato-Oncology, Tripoli Children Hospital, Tripoli University, Tripoli, Libya
,
Raza Ali Akbar
3   Department of Medicine, Hamad General Hospital, Doha, Qatar
,
Fahmi Yousef Khan
3   Department of Medicine, Hamad General Hospital, Doha, Qatar
,
Abdul-Naser Elzouki
3   Department of Medicine, Hamad General Hospital, Doha, Qatar
› Institutsangaben
Funding and Sponsorship None.
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Chronic kidney disease (CKD) is one of the most common disabling diseases globally. The main etiopathology of CKD is attributed to progressive renal fibrosis secondary to recurrent renal insults. Anemia is a known complication in CKD patients, associated with higher hospitalization rates and increased mortality risk. CKD-associated anemia (CKD-AA) is either due to true iron deficiency and/or functional iron deficiency anemia. There is new emerging evidence about the effects of erythropoiesis stimulating agents in the treatment of CKD-AA and their role in reversing and preventing kidney fibrosis in the early stages of CKD. This effect potentially provides new scopes in the prevention and treatment of CKD-AA and in decreasing the progression of CKD and the associated long-term complications. Epidemiology, pathophysiology, and treatments of CKD-AA will be discussed.

Keywords

EPO-H - CKD-AA - hepcidin - CKD anemia - iron therapy - kidney fibrosis

Authors' Contributions

All named authors contributed to the drafting and finalization of the draft.


Compliance with Ethical Principles

No ethical approval is required.




Publikationsverlauf

Artikel online veröffentlicht:
06. Juli 2022

© 2022. The Libyan Authority of Scientific Research and Technology and the Libyan Biotechnology Research Center. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ng JK, Li PK. Chronic kidney disease epidemic: how do we deal with it?. Nephrology (Carlton) 2018; 23 (Suppl. 04) 116-120
    CrossrefPubMedSuche in Google Scholar
  • 2 Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017; 389 (10075): 1238-1252
    CrossrefPubMedSuche in Google Scholar
  • 3 Zhang L, Wang F, Wang L. et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379 (9818): 815-822
    CrossrefPubMedSuche in Google Scholar
  • 4 Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care 2008; 35 (02) 329-344 , vii
    CrossrefPubMedSuche in Google Scholar
  • 5 Locatelli F, Bárány P, Covic A. et al; ERA-EDTA ERBP Advisory Board. Kidney Disease Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28 (06) 1346-1359
    CrossrefPubMedSuche in Google Scholar
  • 6 Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162 (12) 1401-1408
    CrossrefPubMedSuche in Google Scholar
  • 7 McClellan WM, Resnick B, Lei L. et al. Prevalence and severity of chronic kidney disease and anemia in the nursing home population. J Am Med Dir Assoc 2010; 11 (01) 33-41
    CrossrefPubMedSuche in Google Scholar
  • 8 Jones CS, Smith D, Nag S, Bilous TM, Winship S, Wood A, Bilous WR. Prevalence and nature of anaemia in a prospective, population? based sample of people with diabetes: teesside anaemia in diabetes (TAD) study. Diabetic Medicine 2010; Jun; 27 (06) 655-659
    CrossrefPubMedSuche in Google Scholar
  • 9 Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 2018; 94 (01) 178-186
    CrossrefPubMedSuche in Google Scholar
  • 10 Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014; 9 (01) e84943
    CrossrefPubMedSuche in Google Scholar
  • 11 Li Y, Shi H, Wang WM. et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore) 2016; 95 (24) e3872
    CrossrefPubMedSuche in Google Scholar
  • 12 Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91 (01) 31-38
    CrossrefPubMedSuche in Google Scholar
  • 13 Kühn LC. Iron regulatory proteins and their role in controlling iron metabolism. Metallomics 2015; 7 (02) 232-243
    CrossrefPubMedSuche in Google Scholar
  • 14 Kulaksiz H, Fein E, Redecker P, Stremmel W, Adler G, Cetin Y. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol 2008; 197 (02) 241-249
    CrossrefPubMedSuche in Google Scholar
  • 15 Backe MB, Moen IW, Ellervik C, Hansen JB, Mandrup-Poulsen T. Iron regulation of pancreatic beta-cell functions and oxidative stress. Annu Rev Nutr 2016; 36: 241-273
    CrossrefPubMedSuche in Google Scholar
  • 16 Zhou Z, Ribas V, Rajbhandari P. et al. Estrogen receptor α protects pancreatic β-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress. J Biol Chem 2018; 293 (13) 4735-4751
    CrossrefPubMedSuche in Google Scholar
  • 17 Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80 (03) 240-244
    CrossrefPubMedSuche in Google Scholar
  • 18 Santos-Silva A, Ribeiro S, Reis F, Belo L. Hepcidin in chronic kidney disease anemia. Vitam Horm 2019; 110: 243-264
    CrossrefPubMedSuche in Google Scholar
  • 19 Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122 (2-3): 78-86
    CrossrefPubMedSuche in Google Scholar
  • 20 Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92 (12) 5510-5514
    CrossrefPubMedSuche in Google Scholar
  • 21 Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114 (10) 2015-2019
    CrossrefPubMedSuche in Google Scholar
  • 22 Leung PS, Srai SK, Mascarenhas M, Churchill LJ, Debnam ES. Increased duodenal iron uptake and transfer in a rat model of chronic hypoxia is accompanied by reduced hepcidin expression. Gut 2005; 54 (10) 1391-1395
    CrossrefPubMedSuche in Google Scholar
  • 23 Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun 2007; 356 (01) 312-317
    CrossrefPubMedSuche in Google Scholar
  • 24 Idris I, Tohid H, Muhammad NA. et al. Anaemia among primary care patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD): a multicentred cross-sectional study. BMJ Open 2018; 8 (12) e025125
    CrossrefPubMedSuche in Google Scholar
  • 25 Stevens PE. Anaemia, diabetes and chronic kidney disease: where are we now?. J Ren Care 2012; 38 (Suppl. 01) 67-77
    CrossrefPubMedSuche in Google Scholar
  • 26 Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol 2019; 142 (01) 44-50
    CrossrefPubMedSuche in Google Scholar
  • 27 Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2009; 14 (02) 240-246
    CrossrefPubMedSuche in Google Scholar
  • 28 Kliger AS, Foley RN, Goldfarb DS. et al. KDOQI us commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013; 62 (05) 849-859
    CrossrefPubMedSuche in Google Scholar
  • 29 Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis 2016; 68 (05) 677-690
    CrossrefPubMedSuche in Google Scholar
  • 30 Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90 (01) 12-23
    CrossrefPubMedSuche in Google Scholar
  • 31 Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 2006; 3 (1-2): 94-100
    CrossrefPubMedSuche in Google Scholar
  • 32 Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66 (02) 753-760
    CrossrefPubMedSuche in Google Scholar
  • 33 Hu MC, Shi M, Cho HJ. et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int 2013; 84 (03) 468-481
    CrossrefPubMedSuche in Google Scholar
  • 34 Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-a systematic literature review. Int J Nephrol 2020; 2020: 7692376
    CrossrefPubMedSuche in Google Scholar
  • 35 Zhang Y, Zhu X, Huang X. et al. Advances in understanding the effects of erythropoietin on renal fibrosis. Front Med (Lausanne) 2020; 7: 47
    CrossrefPubMedSuche in Google Scholar
  • 36 Elliott S, Busse L, Swift S. et al. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 2012; 27 (07) 2733-2745
    CrossrefPubMedSuche in Google Scholar
  • 37 Endre ZH, Walker RJ, Pickering JW. et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77 (11) 1020-1030
    CrossrefPubMedSuche in Google Scholar
  • 38 Geng XC, Hu ZP, Lian GY. Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation. Mol Med Rep 2015; 11 (05) 3860-3865
    CrossrefPubMedSuche in Google Scholar
  • 39 Souma T, Nezu M, Nakano D. et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J Am Soc Nephrol 2016; 27 (02) 428-438
    CrossrefPubMedSuche in Google Scholar
  • 40 Fischer C, Deininger N, Wolf G, Loeffler I. CERA attenuates kidney fibrogenesis in the db/db mouse by influencing the renal myofibroblast generation. J Clin Med 2018; 7 (02) 1-14
    CrossrefPubMedSuche in Google Scholar
  • 41 Abate M, Festa A, Falco M. et al. Mitochondria as playmakers of apoptosis, autophagy and senescence. Semin Cell Dev Biol 2020; 98: 139-153
    CrossrefPubMedSuche in Google Scholar
  • 42 Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998; 83 (08) 724-732
    PubMedSuche in Google Scholar
  • 43 Morgado-Pascual JL, Marchant V, Rodrigues-Diez R. et al. Epigenetic modification mechanisms involved in inflammation and fibrosis in renal pathology. Mediators Inflamm 2018; 2018: 2931049
    CrossrefPubMedSuche in Google Scholar
  • 44 Mateus V, Rocha J, Alves P, Mota-Filipe H, Sepodes B, Pinto RM. Anti-inflammatory effect of erythropoietin in the TNBS-induced colitis. Basic Clin Pharmacol Toxicol 2017; 120 (02) 138-145
    CrossrefPubMedSuche in Google Scholar
  • 45 Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero J-J. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J 2020; 13 (05) 821-827
    CrossrefPubMedSuche in Google Scholar
  • 46 Ryter SW, Mizumura K, Choi AM. The impact of autophagy on cell death modalities. Int J Cell Biol 2014; 2014: 502676
    CrossrefPubMedSuche in Google Scholar
  • 47 Yu Y, Shiou SR, Guo Y. et al. Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis. PLoS One 2013; 8 (07) e69620
    CrossrefPubMedSuche in Google Scholar
  • 48 Yang C, Xu Z, Zhao Z. et al. A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney ischemia reperfusion injury. Biochim Biophys Acta 2014; 1842 (11) 2306-2317
    CrossrefPubMedSuche in Google Scholar
  • 49 Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol 2019; 14 (01) 28-39
    CrossrefPubMedSuche in Google Scholar
  • 50 Regidor DL, Kopple JD, Kovesdy CP. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17 (04) 1181-1191
    CrossrefPubMedSuche in Google Scholar
  • 51 Singh AK, Szczech L, Tang KL. et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20) 2085-2098
    CrossrefPubMedSuche in Google Scholar